In this retrospective analysis of 40,812 patients hospitalized with an MI, researchers analyzed the risk of bleeding-related hospitalizations according to different anti-thrombotic medication regimens (combinations of ASA, clopidogrel, and vitamin K antagonists). After a mean follow up of 1.3 years, the overall risk of bleeding-related hospitalizations was 5%. The annual risk for all monotherapy groups, the ASA+clopidogrel, and the ASA+vitamin K antagonist groups were between 3-5%, but was 12% for the clopidogrel + vitamin K and the triple therapy groups. The most common non-fatal bleeding was GI, and the most fatal bleeding was related to femoral pseudoaneurysms. This study helps quantify the risks of bleeding-related re-hospitalizations in patients being discharged on anti-thrombotic combinations (abstract)
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment